NZ335003A - Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1) - Google Patents
Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)Info
- Publication number
- NZ335003A NZ335003A NZ335003A NZ33500397A NZ335003A NZ 335003 A NZ335003 A NZ 335003A NZ 335003 A NZ335003 A NZ 335003A NZ 33500397 A NZ33500397 A NZ 33500397A NZ 335003 A NZ335003 A NZ 335003A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mpif
- inhibitory factor
- myeloid progenitor
- methods
- disease states
- Prior art date
Links
- 102100036850 C-C motif chemokine 23 Human genes 0.000 title abstract 6
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000003525 myelopoietic effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2729996P | 1996-09-30 | 1996-09-30 | |
US2730096P | 1996-09-30 | 1996-09-30 | |
PCT/US1997/017505 WO1998014582A1 (en) | 1996-09-30 | 1997-09-30 | Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4) |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ335003A true NZ335003A (en) | 2000-11-24 |
Family
ID=26702293
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ506135A NZ506135A (en) | 1996-09-30 | 1997-09-30 | Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis |
NZ335003A NZ335003A (en) | 1996-09-30 | 1997-09-30 | Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ506135A NZ506135A (en) | 1996-09-30 | 1997-09-30 | Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0941330A1 (ja) |
JP (1) | JP2001500382A (ja) |
KR (1) | KR20030097607A (ja) |
CN (1) | CN1239510A (ja) |
AU (1) | AU4657697A (ja) |
CA (1) | CA2267193A1 (ja) |
NZ (2) | NZ506135A (ja) |
WO (1) | WO1998014582A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451562B1 (en) | 1993-12-22 | 2002-09-17 | Human Genome Sciences, Inc. | Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides |
US6811773B1 (en) | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
US6001606A (en) * | 1994-03-08 | 1999-12-14 | Human Genome Sciences, Inc. | Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby |
US6488925B2 (en) | 1993-12-22 | 2002-12-03 | Human Genome Sciences, Inc. | Macrophage inflammatory protein-4 (MIP-4) polypeptides |
US6495129B1 (en) | 1994-03-08 | 2002-12-17 | Human Genome Sciences, Inc. | Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) |
AU777297B2 (en) * | 1996-09-30 | 2004-10-07 | Human Genome Sciences, Inc. | Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4) |
US6632425B1 (en) | 1997-03-20 | 2003-10-14 | Human Genome Sciences, Inc. | Chemokine compositions |
US6495128B1 (en) | 1998-11-10 | 2002-12-17 | Human Genome Sciences, Inc. | Human chemokine β-7 deletion and substitution proteins |
EP1142908A4 (en) * | 1999-01-07 | 2002-05-22 | Takeda Chemical Industries Ltd | PROCESS FOR PRODUCING ACTIVATED PROTEINS |
JP2003516934A (ja) * | 1999-10-14 | 2003-05-20 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | ヒト骨髄前駆細胞阻害性因子−1(mpif−1)を用いる、細胞、組織および器官の損傷を処置または予防する方法 |
EP1176200A3 (de) | 2000-06-20 | 2005-01-12 | Switch Biotech Aktiengesellschaft | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen |
US20030096260A1 (en) * | 2001-10-09 | 2003-05-22 | Zhenhua Miao | Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
US20030215460A1 (en) * | 2002-05-07 | 2003-11-20 | Schall Thomas J. | Methods and compositions for inducing an immune response |
KR100867257B1 (ko) * | 2001-10-09 | 2008-11-11 | 케모센트릭스, 인크. | 포밀 펩티드 수용체 유사 1 수용체에 대한 리간드로유용한 조성물 및 이의 사용 방법 |
EP1675870A1 (en) * | 2003-10-24 | 2006-07-05 | IPF Pharmaceuticals GmbH | Human chemokine hcc-1 polypeptides to improve stem cell transplantation |
US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
CN1930476A (zh) * | 2004-03-22 | 2007-03-14 | 诺瓦提斯公司 | 趋化因子ccl18作为生物标记 |
US8221995B2 (en) | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
CA2701945A1 (en) * | 2007-10-22 | 2009-04-30 | Samuel Norbert Breit | Methods of prognosis of overall survival using mic-1 |
CN113215085B (zh) * | 2021-05-07 | 2024-05-10 | 澳门大学 | 一种脂类物质添加剂及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0735818T3 (da) * | 1993-12-22 | 2004-07-26 | Human Genome Sciences Inc | Makrofag-inflammatoriske proteiner MIP-3, Mip-4 og Mip-1gamma |
DE59410132D1 (de) * | 1993-12-24 | 2002-07-11 | Forssmann Wolf Georg | Humanes zirkulierendes cytokin cc-1 |
US5602008A (en) * | 1994-11-29 | 1997-02-11 | Incyte Pharmaceuticals, Inc. | DNA encoding a liver expressed chemokine |
KR19990008335A (ko) * | 1995-05-05 | 1999-01-25 | 로버트 에리치. 벤슨 | 인체 케모킨 베타-8, 케모킨 베타-1 및 대식세포 염증 단백질-4 |
KR20030096447A (ko) * | 1995-09-29 | 2003-12-31 | 스미스클라인 비참 코포레이션 | 단축형 케모킨 베타-8 |
DE69631253T2 (de) * | 1995-10-24 | 2004-11-18 | Human Genome Sciences, Inc. | Mobilisierung von haematopoietischen stammzellen durch ein chemokin |
-
1997
- 1997-09-30 CN CN97199629A patent/CN1239510A/zh active Pending
- 1997-09-30 AU AU46576/97A patent/AU4657697A/en not_active Abandoned
- 1997-09-30 EP EP97945352A patent/EP0941330A1/en not_active Withdrawn
- 1997-09-30 NZ NZ506135A patent/NZ506135A/xx unknown
- 1997-09-30 KR KR1020027012833A patent/KR20030097607A/ko not_active Application Discontinuation
- 1997-09-30 NZ NZ335003A patent/NZ335003A/xx unknown
- 1997-09-30 WO PCT/US1997/017505 patent/WO1998014582A1/en not_active Application Discontinuation
- 1997-09-30 JP JP10516753A patent/JP2001500382A/ja not_active Withdrawn
- 1997-09-30 CA CA002267193A patent/CA2267193A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1998014582A1 (en) | 1998-04-09 |
EP0941330A1 (en) | 1999-09-15 |
KR20030097607A (ko) | 2003-12-31 |
JP2001500382A (ja) | 2001-01-16 |
CN1239510A (zh) | 1999-12-22 |
NZ506135A (en) | 2002-11-26 |
CA2267193A1 (en) | 1998-04-09 |
AU4657697A (en) | 1998-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ335003A (en) | Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1) | |
EP0735893A4 (en) | CHANGING THE IMMUNE RESPONSE BY USING PAN DR BINDING PROTEINS | |
AU1049788A (en) | Methods and peptides for the treatment of non-ige-mediated diseases | |
HK184896A (en) | Pharmaceutical composition comprising loratadine ibuprofen and pseudoephedrine | |
SG47766A1 (en) | CD2-binding domain of lymphocyte function associated antigen 3 | |
GB9416442D0 (en) | Therapeutic heterocycles | |
GB9806632D0 (en) | Peptide factor | |
ES2091906T3 (es) | Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia. | |
GEP20074095B (en) | Analogs of human insulin modified at position 29 of the b chain thereof | |
DE69912434D1 (de) | Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung | |
HK1123741A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders (dextromethorphan)(quinidine) | |
HK1019856A1 (en) | Therapeutic uses of bpi protein products for human meningococcemia | |
JPH06329549A (ja) | インターロイキン12のp40サブユニットを含んでなる医薬 | |
CA2068871A1 (en) | Non-glycosylated fgf-4 and compositions containing the same | |
DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
CA2123315A1 (en) | Therapeutic agents which are antagonists or partial agonists of human interleukin 4 | |
DE69429365D1 (de) | Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden | |
DE69911401D1 (en) | Immunoregulator | |
ES2150901T3 (es) | Antagonistas de hormonas del crecimiento. | |
CA2094275A1 (en) | Methods and compositions for the treatment of cell proliferation disorders | |
HU9202075D0 (en) | Bcrf1 proteins of gamma-interferon inhibiting effect | |
NO983238L (no) | Exodus kjemokin materialer og fremgangsmÕter | |
WO1996020950A3 (en) | Compositions and methods for treating rheumatoid arthritis | |
AU4762893A (en) | Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases. | |
ES2181915T3 (es) | Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |